liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Omalizumab is effective in treating severe asthma in patients with severe cardiovascular complications and its effects on sCD200, d-dimer, CXCL8, 25-hydroxyvitamin D and IL-1 beta levels
Antalya Training and Research Hospital, Turkey .
Akdeniz University Hospital, Turkey .
Linköping University, Department of Clinical and Experimental Medicine, Division of Clinical Sciences. Linköping University, Faculty of Health Sciences.
German Cancer Research Centre, Germany .
Show others and affiliations
2013 (English)In: Expert Opinion on Biological Therapy, ISSN 1471-2598, Vol. 13, no 9, 1335-1341 p.Article in journal (Refereed) Published
Abstract [en]

Background: There have been concerns about the cardiovascular safety of omalizumab. less thanbrgreater than less thanbrgreater thanObjectives: In this study, the clinical status of the omalizumab receiving severe asthma patients and the cytokine expressions patterns were investigated. less thanbrgreater than less thanbrgreater thanMaterials and methods: In a pilot study described below we examined the levels of serum eosinophil cationic peptid (ECP), CD200, d-dimer, 25-hydroxyvitamin D (25(OH) D), CXCL8 and IL-1 beta in asthma patients treated with anti-IgE therapy, to explore their relationship with disease activity, and the impact of anti-IgE therapy impact on those levels. Exercise stress testing and blood samples were taken at all follow up visits from the time of first diagnosis and after 20 months of treatment during the disease remission. less thanbrgreater than less thanbrgreater thanResults: Fractional exhaled nitric oxide concentrations and serum levels of sTRAIL, sCD200, D-dimer, ECP, total IgE, IL-1 beta and Hs-CRP were decreased while CXCL8, 25(OH) D were increased after starting the treatment of anti-IgE. Our first case of a patient, who had both protein C and S deficiency and hence a high risk for thromboembolism, documents for the first time the safety of omalizumab for asthmatic patients with concurrent risk factors contributing to arteriothrombotic events. less thanbrgreater than less thanbrgreater thanConclusion: Omalizumab might be used carefully in patients with cardiovascular diseases.

Place, publisher, year, edition, pages
Informa Healthcare , 2013. Vol. 13, no 9, 1335-1341 p.
Keyword [en]
25-hydroxyvitamin D, asthma, cardiovascular risk, CXCL8, IL-1 beta, omalizumab, protein C and S deficiency, sCD200
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-97236DOI: 10.1517/14712598.2013.819338ISI: 000322915700012OAI: diva2:646169
Available from: 2013-09-06 Created: 2013-09-05 Last updated: 2014-08-26

Open Access in DiVA

No full text

Other links

Publisher's full text
By organisation
Division of Clinical SciencesFaculty of Health Sciences
In the same journal
Expert Opinion on Biological Therapy
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 37 hits
ReferencesLink to record
Permanent link

Direct link